Literature DB >> 15028636

Normal serum aminotransferase concentration and risk of mortality from liver diseases: prospective cohort study.

Hyeon Chang Kim1, Chung Mo Nam, Sun Ha Jee, Kwang Hyub Han, Dae Kyu Oh, Il Suh.   

Abstract

OBJECTIVE: To examine the relation between the normal range of serum aminotransferase concentration and mortality from liver disease.
DESIGN: Prospective cohort study.
SETTING: Korea Medical Insurance Corporation study with eight years' follow up. PARTICIPANTS: 94,533 men and 47,522 women aged 35-59 years. MAIN OUTCOME MEASURE: Mortality from liver diseases according to death certificate.
RESULTS: There was a positive association between the aminotransferase concentration, even within normal range (35-40 IU/l), and mortality from liver disease. Compared with the concentration < 20 IU/l, the adjusted relative risks for an aspartate aminotransferase concentration of 20-29 IU/l and 30-39 IU/l were 2.5 (95% confidence interval 2.0 to 3.0) and 8.0 (6.6 to 9.8) in men and 3.3 (1.7 to 6.4) and 18.2 (8.1 to 40.4) in women, respectively, The corresponding risks for alanine aminotransferase were 2.9 (2.4 to 3.5) and 9.5 (7.9 to 11.5) in men and 3.8 (1.9 to 7.7) and 6.6 (1.5 to 25.6) in women, respectively. According to receiver operating characteristic curves the best cut-off values for the prediction of liver disease in men were 31 IU/l for aspartate aminotransferase and 30 IU/l for alanine aminotransferase.
CONCLUSION: People with slightly increased aminotransferase activity, but still within the normal range, should be closely observed and further investigated for liver diseases.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15028636      PMCID: PMC404493          DOI: 10.1136/bmj.38050.593634.63

Source DB:  PubMed          Journal:  BMJ        ISSN: 0959-8138


  20 in total

Review 1.  Evaluation of abnormal liver-enzyme results in asymptomatic patients.

Authors:  D S Pratt; M M Kaplan
Journal:  N Engl J Med       Date:  2000-04-27       Impact factor: 91.245

2.  Alanine aminotransferase levels: what's normal?

Authors:  Marshall M Kaplan
Journal:  Ann Intern Med       Date:  2002-07-02       Impact factor: 25.391

3.  Factors associated with serum alanine transaminase activity in healthy subjects: consequences for the definition of normal values, for selection of blood donors, and for patients with chronic hepatitis C. MULTIVIRC Group.

Authors:  A Piton; T Poynard; F Imbert-Bismut; L Khalil; J Delattre; E Pelissier; N Sansonetti; P Opolon
Journal:  Hepatology       Date:  1998-05       Impact factor: 17.425

4.  Liver steatosis in juvenile obesity: correlations with lipid profile, hepatic biochemical parameters and glycemic and insulinemic responses to an oral glucose tolerance test.

Authors:  G Guzzaloni; G Grugni; A Minocci; D Moro; F Morabito
Journal:  Int J Obes Relat Metab Disord       Date:  2000-06

5.  Natural history of hepatitis C virus carriers with persistently normal aminotransferase levels.

Authors:  M Persico; E Persico; R Suozzo; S Conte; M De Seta; L Coppola; B Palmentieri; F C Sasso; R Torella
Journal:  Gastroenterology       Date:  2000-04       Impact factor: 22.682

6.  Clinical features of hepatitis C-infected patients with persistently normal alanine transaminase levels in the Southwestern United States.

Authors:  M M Jamal; A Soni; P G Quinn; D E Wheeler; S Arora; D E Johnston
Journal:  Hepatology       Date:  1999-11       Impact factor: 17.425

7.  Predictive value of ALT levels for histologic findings in chronic hepatitis C: a European collaborative study.

Authors:  Pierre Pradat; Alfredo Alberti; Thierry Poynard; Juan-Ignacio Esteban; Ola Weiland; Patrick Marcellin; Salvatore Badalamenti; Christian Trépo
Journal:  Hepatology       Date:  2002-10       Impact factor: 17.425

8.  High ALT levels predict viremia in anti-HCV-positive HD patients if a modified normal range of ALT is applied.

Authors:  M Espinosa; A Martin-Malo; M A Alvarez de Lara; S Soriano; P Aljama
Journal:  Clin Nephrol       Date:  2000-08       Impact factor: 0.975

9.  Updated definitions of healthy ranges for serum alanine aminotransferase levels.

Authors:  Daniele Prati; Emanuela Taioli; Alberto Zanella; Emanuela Della Torre; Sonia Butelli; Emanuela Del Vecchio; Luciana Vianello; Francesco Zanuso; Fulvio Mozzi; Silvano Milani; Dario Conte; Massimo Colombo; Girolamo Sirchia
Journal:  Ann Intern Med       Date:  2002-07-02       Impact factor: 25.391

10.  The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 report.

Authors:  Aram V Chobanian; George L Bakris; Henry R Black; William C Cushman; Lee A Green; Joseph L Izzo; Daniel W Jones; Barry J Materson; Suzanne Oparil; Jackson T Wright; Edward J Roccella
Journal:  JAMA       Date:  2003-05-14       Impact factor: 56.272

View more
  186 in total

1.  Liver function tests: defining what's normal.

Authors:  Paul Roderick
Journal:  BMJ       Date:  2004-04-24

2.  Metabolic markers and ALT cutoff level for diagnosing nonalcoholic fatty liver disease: a community-based cross-sectional study.

Authors:  Teruki Miyake; Teru Kumagi; Masashi Hirooka; Mitsuhito Koizumi; Shinya Furukawa; Teruhisa Ueda; Yoshio Tokumoto; Yoshio Ikeda; Masanori Abe; Kohichiro Kitai; Yoichi Hiasa; Bunzo Matsuura; Morikazu Onji
Journal:  J Gastroenterol       Date:  2012-02-14       Impact factor: 7.527

3.  Management of chronic hepatitis B with nucleoside or nucleotide analogues: a review of current guidelines.

Authors:  Moon Seok Choi; Byung Chul Yoo
Journal:  Gut Liver       Date:  2010-03-25       Impact factor: 4.519

4.  Characteristics of chronic hepatitis B patients who underwent liver biopsies.

Authors:  W Chotiyaputta; B Degertekin; B J McKenna; N Samala; R J Fontana; A S F Lok
Journal:  J Viral Hepat       Date:  2010-08-17       Impact factor: 3.728

5.  Clinical, laboratory and histological associations in adults with nonalcoholic fatty liver disease.

Authors:  Brent A Neuschwander-Tetri; Jeanne M Clark; Nathan M Bass; Mark L Van Natta; Aynur Unalp-Arida; James Tonascia; Claudia O Zein; Elizabeth M Brunt; David E Kleiner; Arthur J McCullough; Arun J Sanyal; Anna Mae Diehl; Joel E Lavine; Naga Chalasani; Kris V Kowdley
Journal:  Hepatology       Date:  2010-09       Impact factor: 17.425

6.  Low Alanine Aminotransferase Levels in the Elderly Population: Frailty, Disability, Sarcopenia, and Reduced Survival.

Authors:  Umberto Vespasiani-Gentilucci; Antonio De Vincentis; Luigi Ferrucci; Stefania Bandinelli; Raffaele Antonelli Incalzi; Antonio Picardi
Journal:  J Gerontol A Biol Sci Med Sci       Date:  2018-06-14       Impact factor: 6.053

7.  Elevation of alanine transaminase and markers of liver fibrosis after a mixed meal challenge in individuals with type 2 diabetes.

Authors:  E Y H Khoo; M C Stevenson; E Leverton; R Cross; J W Eriksson; S M Poucher; I Spendlove; P G Morris; I A Macdonald; P Mansell; G P Aithal
Journal:  Dig Dis Sci       Date:  2012-05-17       Impact factor: 3.199

8.  Risky alcohol use and serum aminotransferase levels in HIV-infected adults with and without hepatitis C.

Authors:  Judith I Tsui; Debbie M Cheng; Howard Libman; Carly Bridden; Richard Saitz; Jeffrey H Samet
Journal:  J Stud Alcohol Drugs       Date:  2013-03       Impact factor: 2.582

9.  Association between PNPLA3 (rs738409), LYPLAL1 (rs12137855), PPP1R3B (rs4240624), GCKR (rs780094), and elevated transaminase levels in overweight/obese Mexican adults.

Authors:  Yvonne N Flores; Rafael Velázquez-Cruz; Paula Ramírez; Manuel Bañuelos; Zuo-Feng Zhang; Hal F Yee; Shen-Chih Chang; Samuel Canizales-Quinteros; Manuel Quiterio; Guillermo Cabrera-Alvarez; Nelly Patiño; Jorge Salmerón
Journal:  Mol Biol Rep       Date:  2016-10-17       Impact factor: 2.316

10.  The genetic architecture of liver enzyme levels: GGT, ALT and AST.

Authors:  Jenny H D A van Beek; Marleen H M de Moor; Eco J C de Geus; Gitta H Lubke; Jacqueline M Vink; Gonneke Willemsen; Dorret I Boomsma
Journal:  Behav Genet       Date:  2013-04-12       Impact factor: 2.805

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.